PROVO, Utah–(BUSINESS WIRE)– GeNOsys, Inc. (OTCBB:GNYS.ob – News) announced that it has developed a group of nitric oxide producing products for topical use. The products support blood flow and collagen growth to injured tissue and support the healing process. The products will be available as a cream, gel or wash, depending on the desired application. Several patents have been filed related to the products and the procedures for their use. A patent application has also been filed for a nitric oxide producing product which may be used as a hand sterilizer.

“These products provide GeNOsys a significantly shorter pathway to revenue than that which can be expected from sales of our generator and nitric oxide producing medium,” stated Mr. John W.R. Miller, Chairman of the Board of GeNOsys. “We are continuing work on the generator and expect to be able to provide you with updated information on that project in the near future. We have great expectations for the positive impact our generator will have for medical treatments. We expect the cash flow generated from our topical products will fund the commercialization of the generator. We are working to introduce these products into the marketplace at the earliest date possible and expect sales to be initiated no later than the third quarter of this year.”

About GeNOsys:

GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. The Company is currently working to establish distribution channels for its topical products. For further information, see the Company’s Website at: www.genosysusa.com.

This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.

PROVO, Utah–(BUSINESS WIRE)– GeNOsys, Inc. (OTCBB:GNYS.ob – News) today announced the appointment of two additional directors. Mr. Gordon D. Barker and Mr. Keith L. Merrell have accepted board positions.

Mr. Barker served as the Chief Executive Officer of Thrifty Payless Drug Stores, Inc., a $5.1 billion company, and was instrumental in negotiating its merger with Rite-Aid Drugs. Mr. Barker currently serves on a number of Boards of Directors for both public and private companies, including Vice Chairman and Lead Outside Independent Director of United Natural Foods, Inc., NuMedics, Inc., and American Consulting Technology & Research. Mr. Barker has also served as Chairman of the Juvenile Diabetes Research Foundation International.

Mr. Merrell has made valuable contributions as the Chief Financial Officer of GeNOsys. Prior to joining GeNOsys, he was the Chief Financial Officer of Specialized Health Products, Inc., a public company which developed and manufactured medical devices which required FDA approval before they could be introduced into the marketplace.

“We are very fortunate to have a person with the experience of Mr. Barker join our board. His vision and experience will be invaluable as we develop our product strategies,” stated Mr. John W.R. Miller, Chairman of the Board. “Mr. Merrell is also a valued addition to our board, bringing his financial, manufacturing and FDA regulatory experience.”

About GeNOsys:

GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.

This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.

A copy of the 10Q can be reviewed on the SEC website at the following address:

http://www.sec.gov/Archives/edgar/data/1145328/000101041210000185/f10qq210v6.htm